CDNA NASDAQ
CareDx, Inc
1W: +1.9%
1M: +9.2%
3M: +99.2%
YTD: +268.5%
1Y: +371.1%
3Y: +1228.2%
5Y: -4.2%
$70.53
+1.43 (+2.07%)
Weekly Expected Move ±7.1%
$59
$64
$69
$74
$79
Credit Risk of going bust: lower than 74% of companies Debt: 0.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99.9%), CareDx, Inc would be worth roughly what it owes.
Total debt $19.2M against a stock market value of $3.65B.
Distance to default 8.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $9.6M (short-term plus half of long-term), stock volatility 68.4%; Altman Z'' 5.20. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.05 (down 99.9%), CareDx, Inc would be worth roughly what it owes.
Total debt $19.2M against a stock market value of $3.65B.
Distance to default 8.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $9.6M (short-term plus half of long-term), stock volatility 68.4%; Altman Z'' 5.20. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
2 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
Quant snapshot: HF Sinclair, Intel lead top-rated names; Community Financial System, AXIS Capital Holdings lag
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
30 U.S. stocks flashing Strong Buy ratings as earnings roll in
Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT
How yield surges hit small caps—and why BofA prefers mid caps
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
These ten healthcare stocks posted the biggest September gains
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
Zacks.com featured highlights include CareDx, Ciena, Celestica, Materion and MACOM Technology Solutions
5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential
CareDx (NASDAQ:CDNA) Hits New 1-Year High – Time to Buy?
10 mid-cap healthcare stocks with the strongest momentum grades
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Canada Pension Plan Investment Board Takes Position in CareDx, Inc. $CDNA
CareDx (CDNA) is a Great Momentum Stock: Should You Buy?
Bamco Inc. NY Makes New $55.21 Million Investment in CareDx, Inc. $CDNA
Zacks Industry Outlook CareDx, BrightSpring and PACS
Biotech Breakout: What's in focus after Moderna's cancer win?
3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX - RTTNews
CareDx (CDNA) Following Raised Guidance And Profit Swing, Does The Stock Look Fully Valued - simplywall.st
Key facts: CareDx (CDNA) raises 2026 revenue guide; grants 15,822 RSUs - TradingView
CareDx (NASDAQ:CDNA) Sets New 52-Week High After Strong Earnings
Is CareDx Inc (CDNA) Overvalued After 14.7% Rally? GF Value Says - GuruFocus
CareDx (CDNA) Stock Jumps As Profitability Recasts The Growth Story - simplywall.st
CDNA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $46 - GuruFocus
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why CareDx Stock Jumped Today - The Motley Fool
Why CareDx Stock Jumped Today
Why CareDx Stock Jumped Today
Medical Test Name Explodes To A High After Earnings
Top Midday Gainers
CDNA Looks 77.9% Overvalued on GF Value™ - GuruFocus
CDNA|CareDx Inc|Price:35.400|Chg%:-0.350 - tradingkey.com
CDNA SWOT Analysis: Strong Revenue Growth Amidst Valuation Conce - GuruFocus
CareDx raises 2026 revenue outlook to $490M-$500M as NavDx integration begins
CareDx, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CDNA) 2026-07-30 - Seeking Alpha
CareDx Q2 Earnings Call Highlights
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
CDNA Looks 77.9% Overvalued on GF Value™ Amid Revenue Upgrade - GuruFocus
CareDx revenue jumps 52% to $132 million in Q2 - Quiver Quantitative
CareDx Announces Second Quarter 2026 Financial Results
Ardent Health, Inc. (ARDT) Expected to Beat Earnings Estimates: Should You Buy?
BlackRock (CDNA) discloses 4.66M CareDx shares, a 9% beneficial stake - Stock Titan
Quant snapshot: Bandwidth and Centene Corporation lead top-rated names as Bank of Marin Bancorp and Axos Financial Dynamics lag
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNA
CareDx (CDNA) Is Up 39.4% After Medicare Clarifies Transplant Test Coverage Limits - What's Changed
CareDx (CDNA) Secures Medicare Reimbursement Clarity, Is The Upside Already Priced In?
CareDx (CDNA) Stock May Be Fully Valued Despite Medicare Coverage News
CareDx (CDNA) Stock May Be Fully Valued Despite Medicare Coverage News - Yahoo Finance
Catalyst watch: Farnborough Air Show, Tesla earnings, AMD AI event, and Samsung reveals
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last? - Yahoo Finance
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday - Benzinga
CareDx (CDNA) Secures Medicare Coverage for Molecular Testing - GuruFocus
CareDx shares jump as Medicare finalizes transplant testing coverage policy (CDNA)
CareDx stock surges 20% on Medicare coverage policy - Investing.com
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 - marketscreener.com
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
Medicare Policy Is Expected to Cover Up to 12 Tests After Transplant - Stock Titan
$CDNA stock is up 24% today. Here's what we see in our data. | CDNA Stock News - Quiver Quantitative
How Caredx Inc. (CDNA) Affects Rotational Strategy Timing - Stock Traders Daily
CareDx (CDNA) Following Reimbursement Progress Is The Stock Starting To Look Fully Valued - simplywall.st
CareDx Completes Naveris Acquisition and Expands Oncology Reach
CareDx (CDNA) director receives 1,746-share quarterly stock grant as compensation - Stock Titan
CareDx (CDNA) CEO has 8,511 shares withheld for RSU tax obligations - Stock Titan
CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology
CareDx (CDNA) CCO has shares withheld to cover taxes on RSU vesting - Stock Titan
CareDx (CDNA) general counsel has 997 shares withheld for tax obligations - Stock Titan
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
CareDx buys Naveris, adding a Medicare-covered cancer test - Stock Titan
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
CareDx sells Lab Products business for $171.2M, refocuses on transplant testing - Stock Titan
CDNA: Insider Form 144 to sell 39,500 shares after option exercise (06/29/2026) - Stock Titan
CDNA Forecast — Price Target — Prediction for 2027 - TradingView
CareDx's CEO Sells 17K Shares
CareDx's CEO Sells 17K Shares
CareDx (CDNA) Stock Could Be 1.5% Overvalued After AlloSure Study Buzz - simplywall.st
CareDx (NASDAQ:CDNA) Passes Both the Minervini Trend Template and High Growth Momentum Tests - ChartMill
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last? - Yahoo Finance
How New AlloSure Kidney Prognostic Evidence At CareDx (CDNA) Has Changed Its Investment Story - simplywall.st
CareDx Inc (CDNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey